A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Ibrutinib (Primary) ; Loncastuximab tesirine (Primary)
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors ADC Therapeutics
- 10 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Jan 2019.
- 20 Dec 2018 Status changed from not yet recruiting to recruiting.
- 03 Oct 2018 New trial record